CN114652784B - Compound essential oil with sedative hypnotic and memory improving effects and preparation method thereof - Google Patents
Compound essential oil with sedative hypnotic and memory improving effects and preparation method thereof Download PDFInfo
- Publication number
- CN114652784B CN114652784B CN202210313896.3A CN202210313896A CN114652784B CN 114652784 B CN114652784 B CN 114652784B CN 202210313896 A CN202210313896 A CN 202210313896A CN 114652784 B CN114652784 B CN 114652784B
- Authority
- CN
- China
- Prior art keywords
- essential oil
- parts
- oil
- compound
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 322
- 150000001875 compounds Chemical class 0.000 title claims abstract description 113
- 230000000694 effects Effects 0.000 title claims abstract description 36
- 230000015654 memory Effects 0.000 title claims abstract description 24
- 230000004799 sedative–hypnotic effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 241000132012 Atractylodes Species 0.000 claims abstract description 25
- 244000178870 Lavandula angustifolia Species 0.000 claims abstract description 25
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims abstract description 25
- 239000001102 lavandula vera Substances 0.000 claims abstract description 25
- 235000018219 lavender Nutrition 0.000 claims abstract description 25
- 239000004863 Frankincense Substances 0.000 claims abstract description 22
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 21
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 21
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 27
- 239000007921 spray Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000011159 matrix material Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 18
- 244000062730 Melissa officinalis Species 0.000 claims description 16
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 16
- 239000000865 liniment Substances 0.000 claims description 16
- 239000003921 oil Substances 0.000 claims description 12
- 235000019198 oils Nutrition 0.000 claims description 12
- 241000382455 Angelica sinensis Species 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 10
- 239000002199 base oil Substances 0.000 claims description 9
- 239000012154 double-distilled water Substances 0.000 claims description 9
- -1 fatty acid ester Chemical class 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 230000001804 emulsifying effect Effects 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 230000001914 calming effect Effects 0.000 claims description 5
- 235000013871 bee wax Nutrition 0.000 claims description 4
- 239000012166 beeswax Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000001256 steam distillation Methods 0.000 claims description 4
- 244000144725 Amygdalus communis Species 0.000 claims description 3
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 3
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 3
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 3
- 240000007049 Juglans regia Species 0.000 claims description 3
- 235000009496 Juglans regia Nutrition 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000008168 almond oil Substances 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 239000003240 coconut oil Substances 0.000 claims description 3
- 235000019864 coconut oil Nutrition 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000008169 grapeseed oil Substances 0.000 claims description 3
- 229940119170 jojoba wax Drugs 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000010667 rosehip oil Substances 0.000 claims description 3
- 239000008159 sesame oil Substances 0.000 claims description 3
- 235000011803 sesame oil Nutrition 0.000 claims description 3
- 238000000638 solvent extraction Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 3
- 229940099259 vaseline Drugs 0.000 claims description 3
- 235000020234 walnut Nutrition 0.000 claims description 3
- 239000010497 wheat germ oil Substances 0.000 claims description 3
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 2
- 239000012498 ultrapure water Substances 0.000 claims description 2
- 240000002045 Guettarda speciosa Species 0.000 claims 3
- 239000003883 ointment base Substances 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 16
- 206010022437 insomnia Diseases 0.000 abstract description 16
- 230000013016 learning Effects 0.000 abstract description 11
- 244000061520 Angelica archangelica Species 0.000 abstract description 10
- 208000019116 sleep disease Diseases 0.000 abstract description 4
- 230000002936 tranquilizing effect Effects 0.000 abstract description 4
- 208000020685 sleep-wake disease Diseases 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 2
- 230000004793 poor memory Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 80
- 238000002474 experimental method Methods 0.000 description 49
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 32
- 238000012360 testing method Methods 0.000 description 21
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 19
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 19
- 230000004620 sleep latency Effects 0.000 description 19
- 238000005259 measurement Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 210000001320 hippocampus Anatomy 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 229960003987 melatonin Drugs 0.000 description 13
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 13
- 230000004617 sleep duration Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 230000004622 sleep time Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 230000000971 hippocampal effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- 210000005013 brain tissue Anatomy 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 7
- 238000000222 aromatherapy Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000007958 sleep Effects 0.000 description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 210000003016 hypothalamus Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000009189 diving Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000002267 hypothalamic effect Effects 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 101000831205 Danio rerio Dynein axonemal assembly factor 11 Proteins 0.000 description 4
- 102100024282 Dynein axonemal assembly factor 11 Human genes 0.000 description 4
- 241001559542 Hippocampus hippocampus Species 0.000 description 4
- 101000831210 Homo sapiens Dynein axonemal assembly factor 11 Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 244000001632 Acorus gramineus Species 0.000 description 3
- 235000013073 Acorus gramineus Nutrition 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000006386 memory function Effects 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 229920000223 polyglycerol Polymers 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 2
- 235000007173 Abies balsamea Nutrition 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 239000004857 Balsam Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241000675108 Citrus tangerina Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 244000018716 Impatiens biflora Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000212322 Levisticum officinale Species 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 239000001645 levisticum officinale Substances 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000008454 sleep-wake cycle Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 210000002348 5-ht neuron Anatomy 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 244000304217 Brassica oleracea var. gongylodes Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229940123730 Orexin receptor antagonist Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 101100437310 Rattus norvegicus Bax gene Proteins 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940052296 esters of benzoic acid for local anesthesia Drugs 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940053999 hypnotics and sedatives melatonin receptor agonists Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009225 memory damage Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The application provides compound essential oil and a preparation method thereof, and a product with sedative hypnotic and memory improving effects, and relates to the technical field of natural product application. The compound essential oil comprises the following raw materials in parts by volume: 5 to 10 parts of angelica essential oil, 5 to 20 parts of bighead atractylodes rhizome essential oil, 1 to 5 parts of ligusticum wallichii essential oil, 5 to 20 parts of dried orange peel essential oil, 2 to 8 parts of frankincense essential oil, 0.5 to 1 part of grassleaf sweelflag rhizome essential oil and 10 to 40 parts of lavender essential oil. The preparation method of the compound essential oil comprises the steps of mixing the raw materials. The application also provides a product with sedative hypnotic and memory improving effects, which comprises the compound essential oil. The compound essential oil provided by the application can improve sleep disorder and insomnia, and has the effects of tranquilizing and allaying excitement, relieving poor memory and improving learning and memory.
Description
Technical Field
The invention relates to the technical field of natural product application, in particular to compound essential oil and a preparation method thereof, and a product with sedative hypnotic and memory improving effects.
Background
With the rapid pace of modern society, more and more people suffer from insomnia due to psychological stress and other reasons. Statistics show that about 27% of people worldwide suffer from insomnia, that 3 million insomnia patients are currently in our country, and that this figure is increasing year by year and tending to younger. Insomnia has become a worldwide public health problem, the second only disease to be treated with headache in neurology department clinics. Chronic insomnia may cause physical diseases such as obesity, hypomnesis, diabetes, hypertension, and cardiovascular and cerebrovascular diseases, and mental diseases such as anxiety and depression.
At present, the clinical approach for treating insomnia mainly comprises drug treatment, such as benzodiazepine receptor agonists, melatonin and melatonin receptor agonists, orexin receptor antagonists, antidepressants and the like. However, the long-term administration of the medicine has strong side effects, such as dizziness, addiction and the like. Clinical medication is still in great dispute, so sedative hypnotic drugs with small side effects and better curative effects are still being continuously researched. At present, aromatherapy is used for treating depression, anxiety, insomnia, cognitive ability and other psychological and physiological conditions, and aromatic traditional Chinese medicines play a great role in eliminating dampness, relieving exterior syndrome with aromatics, inducing resuscitation with aromatics, strengthening body resistance to eliminate pathogenic factors, calming heart, calming qi and the like. In particular, the method of absorbing bromine aromatic essential oil is a common technology for treating insomnia and enhancing memory. Although a plurality of aromatic essential oils exist in the market, the compound essential oil under the guidance of medicine theory and Chinese medicine compatibility is still lacking, and meanwhile, a product capable of stably preserving the essential oil is also lacking.
Disclosure of Invention
An object of the present application is to provide a compound essential oil capable of improving insomnia, and another object is to provide an essential oil product capable of improving the problem of volatile and failure of essential oil in daily use.
In order to achieve the above object, the technical scheme of the present application is as follows:
the application provides compound essential oil, which comprises the following raw materials in parts by volume: 5 to 10 parts of angelica essential oil, 5 to 20 parts of bighead atractylodes rhizome essential oil, 1 to 5 parts of ligusticum wallichii essential oil, 5 to 20 parts of dried orange peel essential oil, 2 to 8 parts of frankincense essential oil, 0.5 to 1 part of grassleaf sweelflag rhizome essential oil and 10 to 40 parts of lavender essential oil.
Preferably, the compound essential oil comprises the following raw materials in parts by volume: 5 to 8 parts of angelica essential oil, 8 to 15 parts of bighead atractylodes rhizome essential oil, 2 to 4 parts of ligusticum wallichii essential oil, 8 to 15 parts of dried orange peel essential oil, 2 to 5 parts of frankincense essential oil, 0.5 to 0.8 part of grassleaf sweelflag rhizome essential oil and 15 to 30 parts of lavender essential oil.
The application provides a preparation method of the compound essential oil, which comprises the steps of mixing the raw materials.
Preferably, the angelica essential oil, the bighead atractylodes rhizome essential oil, the ligusticum wallichii essential oil, the dried orange peel essential oil, the frankincense essential oil, the rhizoma acori graminei essential oil and the lavender essential oil are volatile oils prepared by respectively taking angelica sinensis, bighead atractylodes rhizome, ligusticum wallichii, dried orange peel, frankincense, rhizoma acori graminei and lavender as raw materials and adopting a steam distillation method, an organic solvent extraction method, a carbon dioxide supercritical extraction method or a squeezing method.
The application also provides a product with sedative hypnotic and memory improving effects, which comprises the compound essential oil.
Preferably, the product comprises any one of an essential oil balm and an essential oil spray.
Further, the preparation method of the essential oil balm comprises the following steps:
mixing base oil and paste matrix to obtain matrix mixture;
and mixing the compound essential oil with the matrix mixture to obtain the essential oil balm.
Preferably, the base oil comprises at least one of olive oil, sweet almond oil, jojoba oil, wheat germ oil, grape seed oil, coconut oil, sea buckthorn oil, sesame oil, walnut kernel oil and rose hip oil;
the ointment matrix comprises at least one of beeswax, vaseline and solid oil;
preferably, the temperature of the base oil and the paste base when mixed is 50-60 ℃;
preferably, the mass ratio of the compound essential oil to the matrix mixture is 1: (20-40).
Further, the preparation method of the essential oil spray comprises the following steps:
uniformly stirring the compound essential oil and an emulsifying agent to obtain an emulsifying system;
and continuously dripping water into the emulsifying system, and obtaining the essential oil spray after the system is clarified.
Preferably, the emulsifier comprises at least one of polyglycerol fatty acid ester, sucrose fatty acid ester, alkyl polyglucoside;
The water includes any one of double distilled water, deionized water and ultrapure water;
preferably, the stirring rotation speed of the stirring is 50-700 rpm, and the stirring time is 5-60 min.
The invention has the beneficial effects that:
the compound essential oil provided by the application can improve sleep disorder and insomnia, and has the effects of tranquilizing and allaying excitement, relieving poor memory and improving learning and memory. In animal experiments, the compound essential oil achieves hypnotic effect by improving sleep latency and sleep time induced by sodium pentobarbital, improves the content of 5-HT and GABA in hippocampus and hypothalamus, reduces Glu content, and achieves sedative effect; improving MT content in Hippocampus, and further demonstrating that the compound essential oil has sedative effect; by lowering Abeta in serum and sea horse 1-42 Content, thereby indirectly improving memory.
The preparation method of the compound essential oil provided by the application is simple and convenient in steps, and is safe, low in toxicity and less in side effect, and the essential oil extracted from natural plants is used for preparation and production.
The product greatly improves the stability of the compound essential oil, ensures that the active ingredients in the compound essential oil are stably stored, do not degrade or oxidize, and simultaneously effectively improves the irritation generated when the compound essential oil is directly applied to the skin.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are needed in the embodiments will be briefly described below, it being understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope of the present invention.
FIG. 1 is a graph showing the measurement of sleep latency in pentobarbital sodium-induced mice in experiment 3.1;
FIG. 2 is a graph showing the measurement of sleep duration of pentobarbital sodium-induced mice in experiment 3.1;
FIG. 3 is a graph showing the measurement results of the weight change of mice in experiment 3.2;
FIG. 4 (a) is a graph showing the measurement results of the maximum speed of the mice in the open field experiment in experiment 3.3; (b) A graph of the measurement results of the average speed of mice in the open field experiment of experiment 3.3; (c) A graph of the measurement result of the movement distance of the mice in the open field experiment in experiment 3.3;
FIG. 5 is a graph showing the measurement results of the incubation period of the mice in the diving tower experiment of experiment 3.4;
FIG. 6 is a graph showing the measurement results of hippocampal 5-HT in mice from different control groups in experiment 3.5;
FIG. 7 is a graph showing the measurement results of GABA in the hippocampus of mice in the different control groups of experiment 3.5;
FIG. 8 is a graph showing the measurement results of the hippocampal GLU of mice in the different control groups of experiment 3.5;
FIG. 9 is a graph showing the measurement results of the hippocampal Ach of mice in the different control groups in experiment 3.5;
FIG. 10 is a graph showing the hypothalamic 5-HT rate measurements of mice from different control groups in experiment 3.6;
FIG. 11 is a graph showing the measurement results of mouse hypothalamic GABA of the different control groups in experiment 3.6;
FIG. 12 is a graph showing the results of the measurement of mouse hypothalamic GLU in the different control groups of experiment 3.6;
FIG. 13 is a graph showing the measurement results of mouse serum Abeta 1-42 of the different control groups in experiment 3.7;
FIG. 14 is a graph showing the measurement results of the mouse hippocampal Abeta 1-42 of the different control group in experiment 3.7;
FIG. 15 is a graph showing the results of measurement of mouse hippocampal MT in the different control groups of experiment 3.8;
fig. 16 is a diagram showing the change in sleep characteristics of the aged before and after use of the essential oil spray of example 4.
Detailed Description
The term as used herein:
"prepared from … …" is synonymous with "comprising". The terms "comprising," "including," "having," "containing," or any other variation thereof, as used herein, are intended to cover a non-exclusive inclusion. For example, a composition, step, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, step, method, article, or apparatus.
The conjunction "consisting of … …" excludes any unspecified element, step or component. If used in a claim, such phrase will cause the claim to be closed, such that it does not include materials other than those described, except for conventional impurities associated therewith. When the phrase "consisting of … …" appears in a clause of the claim body, rather than immediately following the subject, it is limited to only the elements described in that clause; other elements are not excluded from the stated claims as a whole.
When an equivalent, concentration, or other value or parameter is expressed as a range, preferred range, or a range bounded by a list of upper preferable values and lower preferable values, this is to be understood as specifically disclosing all ranges formed from any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether ranges are separately disclosed. For example, when ranges of "1 to 5" are disclosed, the described ranges should be construed to include ranges of "1 to 4", "1 to 3", "1 to 2 and 4 to 5", "1 to 3 and 5", and the like. When a numerical range is described herein, unless otherwise indicated, the range is intended to include its endpoints and all integers and fractions within the range.
In these examples, the volume fraction represents a basic unit of measurement of the volume relationship of the components, and 1 part may represent an arbitrary unit volume, for example, 1mL, 1. Mu.L, or 1L, 2.689L, or the like. If we say that the volume fraction of the A component is a part and the volume fraction of the B component is B part, the ratio a of the volume of the A component to the volume of the B component is: b. alternatively, the volume fraction of the A component is aK, and the volume fraction of the B component is bK (K is any number and represents a multiple factor). It is not to be misunderstood that the sum of the parts by volume of all the components is not limited to 100 parts.
"and/or" is used to indicate that one or both of the illustrated cases may occur, e.g., a and/or B include (a and B) and (a or B).
The application provides compound essential oil, which comprises the following raw materials in parts by volume: 5 to 10 parts (for example, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts or any value between 5 and 10 parts), 5 to 20 parts (for example, 5 parts, 7 parts, 9 parts, 11 parts, 13 parts, 15 parts, 17 parts, 19 parts, 20 parts or any value between 5 and 20 parts) of white atractylodes rhizome essential oil, 1 to 5 parts (for example, 1 part, 2 parts, 3 parts, 4 parts, 5 parts or any value between 1 and 5 parts) of rhizoma ligustici wallichii essential oil, 5 to 20 parts (for example, 5 parts, 7 parts, 9 parts, 11 parts, 13 parts, 15 parts, 17 parts, 19 parts, 20 parts or any value between 5 and 20 parts) of dried orange peel essential oil, 2 to 8 parts (for example, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts or any value between 2 and 8 parts), 0.5 to 1 part (for example, 0.5 parts, 6 parts, 4 parts, 5 parts, 5.5 parts or any value between 1.5 parts, 10 parts, 0.5 parts or any value between 5.5 parts, 40 parts of lavender essential oil), 0.5 to 20 parts (for example, 0.5 parts, 40 parts or any value between 0.40 parts).
In a preferred embodiment of the present application, the compound essential oil of the present application comprises the following raw materials in parts by volume: 5 to 8 parts of angelica essential oil, 8 to 15 parts of bighead atractylodes rhizome essential oil, 2 to 4 parts of ligusticum wallichii essential oil, 8 to 15 parts of dried orange peel essential oil, 2 to 5 parts of frankincense essential oil, 0.5 to 0.8 part of grassleaf sweelflag rhizome essential oil and 15 to 30 parts of lavender essential oil.
The application provides a preparation method of the compound essential oil, which comprises the steps of mixing the raw materials. The essential oils of Chinese angelica, largehead atractylodes rhizome, szechuan lovage rhizome, tangerine peel, frankincense, grassleaf sweetflag rhizome and lavender are volatile oils prepared by respectively taking Chinese angelica, largehead atractylodes rhizome, szechuan lovage rhizome, tangerine peel, frankincense, grassleaf sweetflag rhizome and lavender as raw materials and adopting a steam distillation method, an organic solvent extraction method, a carbon dioxide supercritical extraction method or a squeezing method.
The angelica essential oil contains a plurality of components such as ligustilide, n-butenolide, angelone, myrcene and the like, has the functions of improving the learning and memory capacity of rats with vascular cognitive dysfunction models, promoting the expression of the rat Bal-2 protein and inhibiting the expression of the rat Bax protein with cognitive dysfunction (VCI) models. Ligustilide has antiasthmatic effect, and can inhibit central nervous system of animal, and ferulic acid can improve peripheral circulation. The main ingredient of the white atractylodes rhizome essential oil is atractylone, and can be used for resisting oxidation, reducing blood sugar, resisting coagulation, resisting bacteria, dilating blood vessels, inhibiting heart, calming and the like. The rhizoma Ligustici Chuanxiong essential oil has effects of inhibiting animal brain activity, inhibiting spontaneous activity of body, prolonging sleep time, and tranquilizing. The pericarpium Citri Tangerinae essential oil and its main ingredient limonene have effects of relieving pain of central nervous system and promoting nerve center to maintain wakefulness, and limonene may achieve tranquilization by regulating dopamine level and 5-HT receptor function. The Olibanum molecules in the essential oil can help relieve dysphoria, frustration, sadness, etc., calm mind, and help meditation. The rhizoma Acori Graminei essential oil has effects of tranquilizing, improving digestive function, relieving asthma and cough, and has good therapeutic effect on some diseases of nervous system. The lavender essential oil has a sedative effect on the heart, can reduce hypertension and calm palpitation, and is helpful for insomnia. Linalool in lavender essential oil can have beneficial effects on memory loss and behavioral modification caused by sleep deprivation by regulating 5-hydroxytryptamine, cortisol levels.
According to the compatibility principles of the same kind of mutual reinforcement, mutual supplement, mutual opposite and the like, the angelica has the effects of nourishing blood and activating blood, the ligusticum wallichii and the frankincense have the effects of activating blood and removing stasis, and promoting blood circulation and dissipating blood, and the mutual supplement has the effects of enhancing and activating blood and removing stasis, and nourishing blood and activating blood circulation; the bighead atractylodes rhizome is more important than tonifying qi, and the dried orange peel is more important than regulating qi, so that the bighead atractylodes rhizome and the dried orange peel complement each other, and the qi is regulated without hurting the qi; rhizoma Acori Graminei has effects of inducing resuscitation, eliminating phlegm, refreshing mind, improving intelligence, eliminating dampness, and stimulating appetite, and has good central nerve treatment effect; lavender is a flower fragrance type essential oil with pleasant smell, can effectively regulate the smell of the traditional Chinese medicine essential oil, and has the function of pleasurable mind and body; in conclusion, the essential oils complement each other and act together.
Through animal experiment researches, the inventor discovers that the compound essential oil obtained by setting the volume parts of the raw material essential oils in the range has the effects of sedative hypnotic and memory improvement.
However, these compound essential oils are all essential oils extracted from plants, are oily liquids, and have high volatility, so that the stability of the compound essential oils is low. Under the conditions of oxygen, illumination and high temperature, the chemical property of the compound essential oil is unstable, and the medicinal active ingredients can be volatilized, degraded and oxidized rapidly, and can be easily crystallized and separated out under the low temperature condition, so that the drug effect of the essential oil is obviously reduced. Especially, if part of the essential oil is directly used, the essential oil is also easy to generate irritation to skin. Therefore, aiming at the problems that the compound essential oil is not easy to store for a long time and skin irritation is easy to generate, the application also provides a product with sedative hypnotic and memory improving effects, which comprises the compound essential oil. Specifically, the product comprises any one of essential oil balm and essential oil spray, can effectively improve the daily application problem of the essential oil, and also has the capabilities of calming and hypnotizing and improving memory.
In one embodiment of the present application, the preparation method of the essential oil balm specifically includes the following steps:
(1) The base oil and the paste matrix are mixed according to the mass ratio of 9:3, stirring at 50-60 ℃ to obtain a matrix mixture; wherein the base oil comprises at least one of olive oil, sweet almond oil, jojoba oil, wheat germ oil, grape seed oil, coconut oil, sea buckthorn oil, sesame oil, walnut kernel oil and rose hip oil; the ointment matrix comprises at least one of beeswax, vaseline and solid oil, wherein the solid oil comprises benzyl esters of benzoic acid and cinnamic acid, lauryl esters, animal and vegetable fatty glyceride, and their mixture;
(2) The compound essential oil and the matrix mixture in the step (1) are mixed according to the mass ratio of 1: mixing (20-40), stirring at 50-60 deg.c until homogeneous, and cooling to obtain the balsam. Preferably, the mass ratio of the compound essential oil to the matrix mixture in the step (1) is 1:20 to obtain the essential oil balm.
Wherein, the mass ratio of the compound essential oil to the matrix mixture is 1: (20 to 40), for example, may be 1: 20. 1: 22. 1: 25. 1: 28. 1: 30. 1: 35. 1:40 or 1: any value of (20-40).
In one embodiment of the present application, a method for preparing an essential oil spray product specifically includes: the compound essential oil and the emulsifier are mixed according to the mass ratio of 1: uniformly stirring the components in the ratio of (1-3), then continuously dripping water into the components, and obtaining the essential oil spray after the system is clear and transparent.
Preferably, the mass ratio of the compound essential oil to the emulsifier is 1:2 are uniformly stirred according to the proportion.
The emulsifier generally needs to be an essential oil emulsifier, and specifically comprises at least one of polyglycerol fatty acid ester, sucrose fatty acid ester and alkyl polyglucoside.
After the compound essential oil and the emulsifier are uniformly mixed, water is continuously added dropwise for stirring, the stirring speed is 50-700 rpm, the stirring time is 5-60 min, and the mass of the water used is about 1.5-2.5 times of the mass of the mixed system of the compound essential oil and the emulsifier when the system is clarified.
When the essential oil spray is prepared by dripping water, double distilled water, deionized water or pure water is usually selected to ensure that no other ionic impurities exist in the water.
The essential oil balm, the essential oil spray and other products provided by the application are flexible in use mode, easy to absorb, safe, low in toxicity and less in side effect, and are all essential oil extracted from natural plants.
Embodiments of the present invention will be described in detail below with reference to specific examples, but it will be understood by those skilled in the art that the following examples are only for illustrating the present invention and should not be construed as limiting the scope of the present invention. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1: compound essential oil
The embodiment provides a compound essential oil, which comprises the following raw materials in parts by volume:
5 parts of Chinese angelica essential oil, 8 parts of bighead atractylodes rhizome essential oil, 3 parts of ligusticum wallichii essential oil, 10 parts of dried orange peel essential oil, 5 parts of frankincense essential oil, 0.5 part of grassleaf sweelflag rhizome essential oil and 30 parts of lavender essential oil.
The specific preparation method of the compound essential oil comprises the following steps: the preparation method comprises the steps of respectively taking angelica sinensis, bighead atractylodes rhizome, ligusticum wallichii, dried orange peel, frankincense, rhizoma acori graminei and lavender as raw materials, preparing different types of volatile oil by adopting a steam distillation method, wherein the volatile oil is essential oil, and then mixing the different types of essential oil according to the formula amount to obtain the compound essential oil. For example, the compound essential oil can be obtained by uniformly mixing 5mL of angelica essential oil, 8mL of bighead atractylodes rhizome essential oil, 3mL of ligusticum wallichii essential oil, 10mL of dried orange peel essential oil, 5mL of frankincense essential oil, 0.5mL of rhizoma acori graminei essential oil and 30mL of lavender essential oil.
Example 2: compound essential oil
The embodiment provides a compound essential oil, which comprises the following raw materials in parts by volume:
10 parts of Chinese angelica essential oil, 20 parts of bighead atractylodes rhizome essential oil, 5 parts of ligusticum wallichii essential oil, 20 parts of dried orange peel essential oil, 8 parts of frankincense essential oil, 1 part of grassleaf sweelflag rhizome essential oil and 40 parts of lavender essential oil.
The specific preparation method is the same as that of example 1.
Example 3: essential oil balm with sedative hypnotic and memory improving effects
The embodiment provides an essential oil balsam with sedative-hypnotic and memory improving effects, which comprises compound essential oil mixed by the following parts by volume: 7 parts of Chinese angelica essential oil, 15 parts of bighead atractylodes rhizome essential oil, 3 parts of ligusticum wallichii essential oil, 15 parts of dried orange peel essential oil, 8 parts of frankincense essential oil, 0.7 part of grassleaf sweelflag rhizome essential oil and 20 parts of lavender essential oil. Specifically, the compound essential oil can be obtained by uniformly mixing 7L of angelica essential oil, 15L of bighead atractylodes rhizome essential oil, 3L of ligusticum wallichii essential oil, 15L of dried orange peel essential oil, 8L of frankincense essential oil, 0.7L of grassleaf sweelflag rhizome essential oil and 20L of lavender essential oil.
The specific preparation method of the essential oil balm comprises the following steps:
(1) Olive oil and beeswax are mixed according to the mass ratio of 9:3, mixing in proportion, and stirring at 60 ℃ to obtain a matrix mixture;
(2) Weighing the matrix mixture in the step (1), and mixing the matrix mixture with compound essential oil in the implementation according to the mass ratio of 20:1, uniformly stirring at 60 ℃, and cooling to obtain the essential oil balm.
Example 4: essential oil spray with sedative hypnotic and memory improving effects
The embodiment provides an essential oil spray with sedative hypnotic and memory improving effects, which comprises compound essential oil mixed by the following parts by volume: 10 parts of Chinese angelica essential oil, 10 parts of bighead atractylodes rhizome essential oil, 5 parts of ligusticum wallichii essential oil, 10 parts of dried orange peel essential oil, 3 parts of frankincense essential oil, 0.8 part of grassleaf sweelflag rhizome essential oil and 25 parts of lavender essential oil.
The specific preparation method of the essential oil spray in the embodiment comprises the following steps:
the compound essential oil and the polyglycerol fatty acid ester of the embodiment are mixed according to the mass ratio of 1:2, continuously stirring at the stirring speed of 500rpm for 30min to obtain an emulsifying system, then continuously dripping double distilled water into the emulsifying system until the system becomes clear, wherein the mass of the double distilled water is about 2 times that of the emulsifying system, and thus the essential oil spray can be obtained.
Comparative example 1: compound essential oil
The comparative example provides a compound essential oil, which comprises the following raw materials in parts by volume:
5 parts of Chinese angelica essential oil, 10 parts of bighead atractylodes rhizome essential oil, 5 parts of ligusticum wallichii essential oil, 10 parts of dried orange peel essential oil and 10 parts of lavender essential oil.
The specific preparation method is the same as that of example 1.
Comparative example 2: compound essential oil
10 parts of angelica essential oil, 10 parts of bighead atractylodes rhizome essential oil, 10 parts of dried orange peel essential oil, 5 parts of frankincense essential oil and 20 parts of lavender essential oil.
The specific preparation method is the same as that of example 1.
It should be noted that, when researching the technical scheme of the application, the inventor of the application performs safety tests on different essential oils in compound essential oil in advance, and finds that the grassleaf sweelflag rhizome essential oil has certain toxicity, and the specific tests are as follows:
acorus gramineus essential oil sniffing toxicity experiment
Randomly dividing 112 KM mice into 7 groups, each group of 16 mice with half male and female, continuously sniffing in a box body of 30cm×30cm for 45min, wherein a blank control group sniffs 8mL blank water mist, and dose 1 group (sniffing with 2.83mL rhizoma Acori Graminei essential oil+5.17 mL double distilled water, and space concentration of rhizoma Acori Graminei essential oil is 104.81 mL/m) 3 ) Dose 2 groups (3.25 mL essential oil+4.75mL double distilled water, and the spatial concentration of rhizoma Acori Graminei essential oil is 120.37 mL/m) 3 ) Dose 3 groups (3.73 mL essential oil+4.27 mL distilled water, spatial concentration of rhizoma Acori Graminei essential oil is 138.14 mL/m) 3 ) Dose 4 groups (4.28 mL essential oil+3.72 mL distilled water, spatial concentration of rhizoma Acori Graminei essential oil is 158.52 mL/m) 3 ) Dose 5 groups (4.92 mL essential oil+3.08mL distilled water, spatial concentration of rhizoma Acori Graminei essential oil is 182.22 mL/m) 3 ) Dose 6 groups (5.65 mL essential oil+2.35 mL distilled water, spatial concentration of rhizoma Acori Graminei essential oil is 209.26 mL/m) 3 ). The survival of mice after bromine absorption in the different dose groups and the blank group are listed in table 5.
Table 1 survival after mice were dosed table
| Grouping | Total number of animals (n) | Number of deaths (m) | Mortality (%) |
| Dose 1 group | 16 | 0 | 0 |
| Dose 2 group | 16 | 0 | 0 |
| Dose 3 group | 16 | 4 | 25 |
| Dose 4 groups | 16 | 12 | 75 |
| Dose 5 group | 16 | 15 | 93.75 |
| Dose 6 group | 16 | 15 | 93.75 |
| Blank group | 16 | 0 | 0 |
Calculating half-lethal dose LD of rhizoma Acori Graminei essential oil concentration of table 1 on mice according to improved kohlrabi method 50 The spatial concentration of the essential oil of the grassleaf sweelflag rhizome is 151.48mL/m 3 When the amount of the administered 8mL is converted, half of the mice in the bromine-absorbing box of 30cm×30cm can die by absorbing bromine, half of the lethal amount of the grassleaf sweelflag rhizome essential oil accounts for 51.12% of the 8mL of the dosage volume.
This indicates that the high concentration of the grassleaf sweelflag rhizome essential oil is toxic, in order to ensure the safety of the compound essential oil, the mixing proportion of the grassleaf sweelflag rhizome essential oil and other essential oils in the formula should be strictly controlled when the compound essential oil is compounded, for example, the volume content of the grassleaf sweelflag rhizome essential oil in the compound essential oil in the embodiment 1-2 of the present application accounts for 0.81-0.96% of the volume content of the total compound essential oil, and the concentration of the grassleaf sweelflag rhizome essential oil in the subsequent sniffing and use process is far lower than LD 50 Is a concentration of (3). Therefore, the use concentration of the compound essential oil in the technical scheme is within the safe concentration range.
The beneficial effects of the compound essential oil provided by the application are specifically illustrated by animal experiments.
1. Experimental animal
The number of male KM mice is 108, the weight is 20+/-2 g, the mice are randomly divided into 6 groups according to the weight, 18 mice in each group are subjected to experiments, and a blank group, a model group, a positive group, a low-dose group, a medium-dose group and a high-dose group are arranged.
2. Experimental medicine
Diazepam tablets; compound essential oil prepared in example 1.
3. Experimental method
The temperature of the feeding environment is 24-26 ℃, the humidity is 50-60%, the brightness and the darkness are alternated for 12 hours, free drinking and feeding are performed during the period, and the experiment is started after one week of adaptive feeding. Except for blank groups, all other groups adopt an intraperitoneal injection of paracetamol animal insomnia model. P-chlorophenylalanine (PCPA) is precisely weighed and prepared into suspension by using normal saline for standby, each mouse is injected with the PCPA suspension according to the dosage of 300mg/kg, the injection is continuously carried out for two days, after the first injection is carried out for 28-32h, the animals have obvious behavioral changes of continuous activities, enhanced excitability, enhanced aggressiveness, grey stool and the like in the day and night, which indicates that the insomnia model of the mice is successfully prepared, and the blank group is treated by injecting the normal saline with the same volume.
After successful modeling, mice in the positive group are given an equal volume of diazepam aqueous solution every day, diazepam is the first choice drug for treating insomnia, and the administration dosage of the mice is 1.3mg/kg according to the surface area conversion formula of the animal administration dosage body. The blank group and the model group irrigate the stomach with equal volume of distilled water, the low dose group, the medium dose group and the high dose group perform the inhalation intervention every day, each dose group inhales the compound essential oil mixed solution mixed by compound essential oil and water with different volume percentage concentrations every day, the volume percentage concentrations are respectively 0.25%, 0.5% and 1%, and the continuous administration is carried out for 7 days.
The animal aromatherapy chamber is a 50X 40cm big box structure made of organic glass, 4 small box structures which are 20X 20cm and can be filled with air are arranged in the animal aromatherapy chamber, an ultrasonic aromatherapy machine can be placed in the middle of the box, mice are sequentially placed in the aromatherapy box, the prepared compound essential oil mixed solution is added into the aromatherapy machine, the box cover is covered, and the mice are inhaled for 60 minutes. The positive group is filled with equal volume of 1.3mg/kg concentration diazepam water solution, and the blank group, the model group and the compound essential oil administration group are filled with equal volume of distilled water.
3.1 sodium pentobarbital-induced sleep latency and sleep duration
9 mice in each group were randomly labeled, and after 30min from the end of the last dose or aromatherapy, the labeled 9 mice in each group were intraperitoneally injected with a threshold dose of 55mg/kg of pentobarbital sodium (pre-experimental results indicated that the experimental animals were 100% asleep at this concentration). After injection, mice were placed on a warm pad and the time to fall asleep was noted, with the disappearance of the eversion of the mice for 1 minute as an indicator of falling asleep. The time from injection of the drug to disappearance of the flip-flop is the latency of the sleep time, the time from disappearance of the flip-flop until restoration is the sleep time, and the latency of the sleep time and the sleep time are recorded.
As shown in fig. 1 and 2, the sleep latency is significantly increased and the sleep duration is significantly reduced in the model group compared to the blank group; the sleep latency is significantly reduced and the sleep duration is significantly enhanced in the group 3 mice with different doses of the positive group and the compound essential oil compared to the model group mice. This shows that the compound essential oil can obviously reduce the sleep latency of mice through the way of sniffing, prolongs the sleep time and is dose-dependent.
3.2 weight changes in mice
Weighing the weight of each group of mice before molding, and recording; after successful molding, the mice in the positive group, the model group and the compound essential oil administration group with different doses are filled with distilled water with the same volume as the positive group, the model group and the compound essential oil administration group, and the mice in the low dose group, the medium dose group and the high dose group are subjected to sniffing intervention every day, and after 7 days of continuous administration, the weights of the mice are weighed before sacrifice, and the weight increment of the mice is calculated before and after the continuous administration.
As shown in fig. 3, the mice in the model group had significantly reduced body weight compared to the blank group; compared with the model group, the body weight of the mice in the positive group and the 3 groups with different doses of compound essential oil is obviously increased.
3.3 open field experiments with mice
Open field experiments were performed using unlabeled mice in experiment 3.1, each group of mice was subjected to an autonomous activity test experiment for each group of mice after 30min of last administration, mice were acclimatized in the environment for 3min, the moving distance, average speed, resting time behavioural parameters were counted for 5min, and differences between the behavioural parameters of each group of mice were compared.
As shown in (a), (b), and (c) of fig. 4, the maximum speed, average speed, and moving distance of the model group are significantly increased compared to the blank group; compared with the model group, the maximum speed, average speed and moving distance of the mice in the positive group and the 3 groups with different doses of compound essential oil are obviously reduced.
3.4 mouse diving experiments
The test of diving platform is carried out on mice in different groups, when the administration is carried out on day 4, the mice are firstly placed on the copper grid, when the copper grid is electrified, the mice which jump on the copper grid receive electric shock, the normal response is to avoid the electric shock jumping on the platform, most of the mice possibly jump down the platform again or repeatedly to receive electric shock, and the mice jump back to the platform quickly when receiving the electric shock. The training was performed for 5 minutes, and the number of electric shocks (number of errors) received by each mouse was recorded as the learning score. And (3) re-testing after 24 hours, wherein the mice are firstly placed on a diving platform during the test, and the time of first jumping (latency period) and the number of errors within 5 minutes are recorded, so that the memory retention condition is reflected.
As shown in fig. 5, the latency of mice in the model group was extremely significantly reduced compared to the blank group; compared with the model group, the latency of the mice in the positive group and the 3 groups with different doses of compound essential oil is obviously increased and dose dependency exists.
3.5 experiments on the Effect of Compound essential oil on the level of mouse Hippocampus 5-HT, GABA, glu, ach
The experiment was performed using the mice in experiment 3.2, and after 30min of last administration on day 7, hippocampal tissue was rapidly isolated. Washing off brain tissue blood and impurities in ice PBS buffer solution, placing brain tissue into a centrifuge tube, adding 9 times of PBS buffer solution with brain tissue weight, homogenizing, centrifuging (6000 r/min,20 min), and collecting supernatant. After the supernatant samples of the brain tissues of each group of mice are treated according to the specification of an enzyme-linked immunosorbent assay (ELISA) kit of the mice 5-HT, GABA, glu, ach, the content of 5-HT, GABA, glu, ach in the sea horse is detected at 450nm by adopting an enzyme-labeled instrument.
5-HT, GABA, glu, ach are all neurotransmitters in the brain, and specifically, 5-HT neurons have an effect of modulating the sleep-wake cycle, and are one of the hinges of sleep and wake. GABA is the most important and abundant inhibitory neurotransmitter in the central nervous system, and hypofunction may lead to insufficient inhibitory function in the brain, etc. Glu is a major excitatory neurotransmitter that maintains normal functions of the nervous system, and is involved in regulating a variety of cellular activities and physiological functions, such as survival and apoptosis, learning, memory, cognition, emotion, and movement of cells. Ach is a very common neurotransmitter, and is an important neurotransmitter involved in learning and memory in cholinergic systems, and damage to cholinergic systems can cause defects in learning and memory functions, and is related to senile hypomnesis, age-related memory damage and the like.
As shown in fig. 6-9, the concentration content of hippocampus 5-HT, GABA, ach was significantly reduced in the model group mice and the concentration content of GLU was significantly increased compared to the blank group; compared with mice in a model group, the concentration content of hippocampus 5-HT, GABA, ach of mice in 3 groups with different doses of positive group and compound essential oil is obviously increased, and the concentration content of GLU is obviously reduced, which indicates that the compound essential oil can achieve sedative hypnotic effect through an inhalation mode.
3.6 experiments on the Effect of Compound essential oil on the hypothalamic 5-HT, GABA, glu level in mice
Experiments were performed using the mice in experiment 3.2, and hypothalamic tissues were rapidly isolated 30min after the last dose on day 7. Washing off brain tissue blood and impurities in ice PBS buffer solution, placing brain tissue into a centrifuge tube, adding 9 times of PBS buffer solution with brain tissue weight, homogenizing, centrifuging (6000 r/min,20 min), and collecting supernatant. Samples of brain tissue supernatant from each group of mice were treated according to the instructions of the enzyme-linked immunosorbent assay (ELISA) kit for mice 5-HT, GABA, glu and the hypothalamus content 5-HT, GABA, glu was detected at 450nm using an ELISA apparatus.
As shown in fig. 10-12, the concentration levels of 5-HT and GABA were significantly reduced in the hypothalamus mice of the model group compared to the blank group, while the concentration level of GLU was significantly increased; compared with the model group, the concentration content of hypothalamus 5-HT and GABA of the 3 groups of mice with the positive group and the compound essential oil with different dosages is obviously increased, and the concentration content of GLU is obviously reduced. This indicates that the compound essential oil can achieve sedative hypnotic effect by inhalation.
3.7 Compound essential oil vs. Abeta in mouse serum and Hippocampus 1-42 Influence of content experiment
Experiments were performed using the mice in experiment 3.2, and after 30min of last administration on day 7, the serum and hippocampal tissues of the mice were removed and were prepared according to aβ 1-42 Kit operations for detection of Abeta in serum and hippocampus 1-42 The content is as follows.
Beta-amyloid protein (Abeta) 1-42 ) Can inhibit proliferation of neural stem cells, destroy neuron membrane, penetrate water and ions and cause cell death,thereby damaging neurons and a large amount of Abeta 1-42 Is easy to reduce the memory and learning and cognition functions of animals.
As shown in fig. 13-14, the serum of mice in the model group and aβ in the hippocampus were compared with the blank group 1-42 The concentration content of (2) is significantly increased; compared with the model group, the serum of 3 groups of mice with different dosages of positive group and compound essential oil and Abeta in sea horse 1-42 The concentration content of (2) is obviously reduced, which indicates that the compound essential oil can obviously reduce Abeta in serum and hippocampus by an olfactory inhalation mode 1-42 Is never indirectly improved in memory function.
3.8 experiment of influence of Compound essential oil on MT content in Hippocampus of mice
Experiments were performed using the mice in experiment 3.2, and after 30min of last administration on day 7, the hippocampal tissues of the mice were removed and operated according to MT kit for detecting MT content in hippocampus.
Melatonin (MT) is an indole hormone secreted by the pineal gland of mammals and humans and has a variety of physiological activities. It can induce natural physiological sleep, correct disordered sleep-wake cycle, and research finds that MT has various pharmacological actions similar to benzodiazepines, such as sedative hypnotic, antiepileptic, etc.; MT can increase GABA content of hypothalamus, brainstem and cerebral cortex, and can enhance central inhibition of GABA by facilitating GABA binding with its receptor in brain.
As shown in fig. 15, the MT content in the hippocampus was significantly reduced in the mice of the model group compared to the blank group; compared with mice in a model group, the MT content in the hippocampus of 3 groups of mice with positive groups and compound essential oil at different doses is obviously increased, which indicates that the compound essential oil can obviously increase the MT content in the hippocampus by an inhalation mode so as to achieve sedative-hypnotic effect.
The experimental results are all statistically analyzed by mean+ -SD and SPSS 25.0 software, the comparison among groups is analyzed by a single-factor ANOVA method, the variance is even by an LSD method, the variance is uneven by a gas-Howell method, in the statistical results, delta P is less than 0.05 and delta P is less than 0.01 compared with a blank group, and P is less than 0.05 and P is less than 0.01 compared with a model group.
The animal experiment results show that the above-mentioned materials,the compound essential oil of the example 1 provided by the application can reduce the sleep latency induced by pentobarbital sodium, prolong the sleep duration, increase the weight, increase the 5-HT and GABA levels in the hippocampus and hypothalamus in the brain and simultaneously reduce the level of hippocampal GLU by sniffing administration so as to achieve the sedative hypnotic effect. Increase learning and memory capacity by increasing diving experiment learning latency, and decrease Abeta in serum and sea horse 1-42 Further improving learning memory and cognitive function.
Animal experiments were also performed in this application on the compound essential oil of example 2, selected animals and experimental methods refer to example 1 above, and finally the sodium pentobarbital-induced sleep latency and sleep duration of mice were tested. Tables 2 and 3 record the data for sleep latency and sleep duration for the different test groups of example 1 and example 2, respectively.
TABLE 2 sleep latency results
Table 3 sleep duration results
| Group of | Example 1 | Example 2 |
| Blank group | 31.45±17.55 | 31.45±18.77 |
| Model group | 20.03±10.31 | 11.22±4.54 |
| Positive group | 49.45±16.19 | 32.00±17.34 |
| Low dose group | 37.35±11.39 | 27.01±16.95 |
| Medium dose group | 38.52±16.58 | 28.81±16.16 |
| High dose group | 41.49±20.33 | 29.30±12.90 |
From tables 2 and 3, the model group in example 2 showed a significant increase in sleep latency and a significant decrease in sleep duration compared to the blank group; the sleep latency was significantly reduced and sleep duration was significantly enhanced in the positive group, the compound essential oil low, medium, and high dose group 3 mice of example 2 compared to the model group mice. This shows that the experimental rule of the compound essential oil in the embodiment 2 of the application in the sleep latency period and the experimental rule of the sleep duration are the same as the experimental rule of the compound essential oil in the embodiment 1, which further indicates that the compound essential oils in the embodiment 1 and the embodiment 2 of the application can obviously reduce the sleep latency period of mice and prolong the sleep time through the sniffing way.
Further analysis found that: the sleep latency and sleep duration of example 1 are dose dependent, while the sleep latency differences between the different dose groups of example 2 are larger, and the sleep duration is shorter than that of example 1, which indicates that example 1 of the present application has better effect in improving sleep disorders, insomnia than that of example 2.
The application also selects some volunteers with sleep disorder for testing, and the specific characteristic analysis is as follows:
40 adults 20-50 years old are selected, each subject is a brain worker, the working time per week is not less than 5 days, the working time per day is not less than 8 hours, the subjects face electronic products (including but not limited to mobile phones and computers) for a long time, the sleep time is >30 minutes, the night wakefulness is equal to or greater than 2 times, the total sleep time is less than 6 hours, the sleep quality is reduced, and the daily dysfunction is accompanied.
The above test volunteers did not participate in any other or adjuvant treatment during the test period, the above group was randomly divided into 4 groups, and subjects in different groups were subjected to the experiment of falling asleep with the prescriptions of example 1, example 2, comparative example 1, comparative example 2, respectively, with "fragrance" before sleeping, and continuously conducted for 2 days, i.e., 1-3 drops of compound essential oil (theoretical 0.05-0.15 mL) were dropped to the fragrance-expanded woods before sleeping every day, and placed at the bedside after absorption. The questionnaire is then completed as if it were filled in according to the test index of table 4 below.
Table 4 test index
Table 5 test results
/>
Table 5 shows the test results of different test groups after 2 days of test, and basically all the test groups subjectively think that after using the compound essential oil, the sleep time is shortened, the sleep time is increased, the dream times are reduced, the night starting times are reduced, the daytime working state is improved, and the like. But the fragrance and comfort level of example 1 and example 2 are more acceptable to people than those of the formulations of comparative example 1 and comparative example 2, and the dream condition, the second day mental state and the night awakening condition, example 1 and example 2 are also superior to comparative example 1 and comparative example 2. After the average calculation of the values of all the test indexes, the average values of the test indexes of the example 1 and the example 2 are also higher than those of the comparative examples 1 and 2. It can be seen that the compound essential oils of example 1 and example 2 of the present application have better sedative-hypnotic effects.
After that, 10 subjects using the compound essential oil of example 1 were counted, and the change of sleep characteristics before and after the test was performed, and the results of the related tests are shown in fig. 16.
The results of fig. 16 show that: the compound essential oil disclosed by the embodiment 1 of the application can be used for remarkably improving the sleep balance index of people with difficult sleep; the sleep latency can be obviously reduced, the average sleep latency after one day is 31.4 minutes, and the average sleep latency after two days is 17.7 minutes; the total sleeping time and sleeping efficiency of the tested person are also improved to a certain extent. In addition, the compound essential oil of example 1 was used without changing the sleep structure ratio of the human subject.
In addition, the application also performs skin irritation and storage stability investigation on the product prepared from the compound essential oil.
Skin irritation investigation of essential oil balm products
SD rats, male and female halves, weigh 180+ -20 g. After separating male and female SD rats, the rats were randomly separated into 6 groups of female rats and 6 groups of male rats according to body weight, and each group was uniformly applied to the backs of rats with 17.5% stock solution (33/40 matrix mixture+7/40 compound essential oil), 25% stock solution (3/4 matrix mixture+1/4 compound essential oil), 35% stock solution (13/20 matrix mixture+7/20 compound essential oil), 50% stock solution (1/2 matrix mixture+1/2 compound essential oil), 70% stock solution (3/10 matrix mixture+7/10 compound essential oil), and 100% stock solution (100% compound essential oil).
Taking 0.5mL of a test medicament to be directly smeared on one side of the back skin of a rat, smearing blank base oil on the other side of the back skin of the rat as a control, then covering with two layers of gauze and one layer of cellophane, fixing by using an adhesive tape, adhering for at least 4 hours, removing the smears after adhering, cleaning by warm water, observing and recording whether the coated parts have erythema and edema by naked eyes respectively at 1 hour, 2 hours, 4 hours, 24 hours, 48 hours and 72 hours, and inspecting whether the parts of the blood vessel, the muscle, the skin, the mucous membrane and the like of the animal cause local reactions such as reddish swelling, hyperemia, exudation, denaturation or necrosis according to the scoring principle specified in the technical guidelines of local irritation and hemolysis research of traditional Chinese medicines and natural medicaments.
TABLE 6 skin changes at various stages in rats
According to the results of the above Table 6, it is shown that the male rats of 100% stock solution group were slightly reddish after 2 hours of administration, and the female rats of 50% stock solution or more were slightly reddish; after 24 hours of administration, 70% of the stock solution groups of the male rats have slight reddening; after 72 hours of administration, the skin of the administered rats was restored to the previous state. Therefore, the essential oil balm prepared by the method is in a reasonable range, and the essential oil balm can reduce the irritation to skin and is safe and effective.
Stability investigation of essential oil spray product
(1) Centrifugal stability
The essential oil spray prepared in example 4 was centrifuged at 8000r/min for 15min, and the appearance after centrifugation was observed for the presence of a delamination demulsification phenomenon. The results show that the spray is still clear and transparent after centrifugation, and is not broken by layering, so that the spray has good centrifugal stability.
(2) Dilution stability
The essential oil spray and double distilled water are diluted according to the proportion of 100, 200, 400, 800 and 1200 times, and whether layering and demulsification of appearance are observed. The results show that no layering phenomenon is observed after the spray is uniformly mixed with double distilled water in any proportion, and the solution uniformity is good, so that the spray has good dilution stability.
(3) Temperature stability
Spraying essential oil in a closed container, standing at 4deg.C, 25deg.C and 37deg.C, and observing appearance change. The results show that the appearance of the oil spray has no layering demulsification phenomenon, and the essential oil spray has temperature stability.
(4) Long term stability
Spraying essential oil into a sealed sample bottle, storing at normal temperature for 60d, and observing the appearance and testing the change of the particle size of the essential oil with the 0d, 7d, 15d, 30d and 60d respectively. The results show that the appearance and the particle size of the oil spray are good, the layering demulsification phenomenon is not seen, and the essential oil spray has long-term stability, as shown in Table 7.
TABLE 7 Long term stability particle size and PDI results
| Days/d | Particle size (nm) | PDI |
| 0 | 26.21±2.73 | 0.30±0.06 |
| 7 | 23.49±0.68 | 0.27±0.02 |
| 15 | 23.90±0.55 | 0.26±0.01 |
| 30 | 22.52±0.41 | 0.23±0.02 |
| 60 | 23.17±0.50 | 0.30±0.01 |
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.
Furthermore, those skilled in the art will appreciate that while some embodiments herein include some features but not others included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention and form different embodiments. For example, in the claims below, any of the claimed embodiments may be used in any combination. The information disclosed in this background section is only for enhancement of understanding of the general background of the invention and should not be taken as an acknowledgement or any form of suggestion that this information forms the prior art already known to a person skilled in the art.
Claims (12)
1. The compound essential oil with the effects of calming and hypnotizing and improving memory is characterized by comprising the following raw materials in parts by volume: 5 to 10 parts of angelica essential oil, 5 to 20 parts of bighead atractylodes rhizome essential oil, 1 to 5 parts of ligusticum wallichii essential oil, 5 to 20 parts of dried orange peel essential oil, 2 to 8 parts of frankincense essential oil, 0.5 to 1 part of grassleaf sweelflag rhizome essential oil and 10 to 40 parts of lavender essential oil.
2. The compound essential oil of claim 1, which is characterized by comprising the following raw materials in parts by volume: 5 to 8 parts of angelica essential oil, 8 to 15 parts of bighead atractylodes rhizome essential oil, 2 to 4 parts of ligusticum wallichii essential oil, 8 to 15 parts of dried orange peel essential oil, 2 to 5 parts of frankincense essential oil, 0.5 to 0.8 part of grassleaf sweelflag rhizome essential oil and 15 to 30 parts of lavender essential oil.
3. A method for preparing the compound essential oil according to any one of claims 1 to 2, comprising mixing the raw materials.
4. The method for preparing compound essential oil according to claim 3, wherein the angelica essential oil, the bighead atractylodes rhizome essential oil, the ligusticum wallichii essential oil, the dried orange peel essential oil, the frankincense essential oil, the rhizoma acori graminei essential oil and the lavender essential oil are volatile oils prepared by respectively taking angelica sinensis, bighead atractylodes rhizome, ligusticum wallichii, dried orange peel, frankincense, rhizoma acori graminei and lavender as raw materials and adopting a steam distillation method, an organic solvent extraction method, a carbon dioxide supercritical extraction method or a squeezing method.
5. A product with sedative hypnotic and memory improving effects, which is characterized by being any one of essential oil balm and essential oil spray;
the raw materials of the product comprise the compound essential oil as claimed in any one of claims 1 to 2.
6. The product of claim 5, wherein the method of preparing the essential oil balm comprises:
mixing base oil and paste matrix to obtain matrix mixture;
and mixing the compound essential oil with the matrix mixture to obtain the essential oil balm.
7. The product of claim 6, wherein the base oil comprises at least one of olive oil, sweet almond oil, jojoba oil, wheat germ oil, grape seed oil, coconut oil, sea buckthorn oil, sesame oil, walnut kernel oil, and rose hip oil;
The ointment base comprises at least one of beeswax, vaseline and solid oil.
8. The product of claim 6, wherein the base oil and the paste base are mixed at a temperature of 50 ℃ to 60 ℃.
9. The product of claim 6, wherein the mass ratio of the compound essential oil to the matrix mixture is 1: (20-40).
10. The product of claim 5, wherein the method of preparing the essential oil spray comprises:
uniformly stirring the compound essential oil and an emulsifying agent to obtain an emulsifying system;
and continuously dripping water into the emulsifying system, and obtaining the essential oil spray after the system is clarified.
11. The product of claim 10, wherein the emulsifier comprises at least one of a polyglycerin fatty acid ester, a sucrose fatty acid ester, an alkyl polyglucoside;
the water includes any one of double distilled water, deionized water and ultrapure water.
12. The product according to claim 10, wherein the stirring speed of the stirring is 50-700 rpm and the stirring time is 5-60 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210313896.3A CN114652784B (en) | 2022-03-28 | 2022-03-28 | Compound essential oil with sedative hypnotic and memory improving effects and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210313896.3A CN114652784B (en) | 2022-03-28 | 2022-03-28 | Compound essential oil with sedative hypnotic and memory improving effects and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114652784A CN114652784A (en) | 2022-06-24 |
| CN114652784B true CN114652784B (en) | 2023-07-21 |
Family
ID=82032724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210313896.3A Active CN114652784B (en) | 2022-03-28 | 2022-03-28 | Compound essential oil with sedative hypnotic and memory improving effects and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114652784B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117442660A (en) * | 2023-10-30 | 2024-01-26 | 成都中医药大学 | Essential oil composition with sleep improving function, composite essential oil nanofiber and textile thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209323B (en) * | 2007-12-21 | 2011-05-18 | 北京中科雍和医药技术有限公司 | Compound essential oil capable of improving sleeping |
| CN103550811A (en) * | 2013-11-08 | 2014-02-05 | 沈卫兰 | Incense oil with effects of calming nerves and aiding sleep, and preparation method thereof |
| CN104740135A (en) * | 2013-12-27 | 2015-07-01 | 杜云花 | Memory improvement medicine |
| CN107233412B (en) * | 2017-05-27 | 2020-07-31 | 江西中医药大学 | Compound essential oil composition for promoting sleep and preparation method and application thereof |
| CN108096445A (en) * | 2018-03-01 | 2018-06-01 | 广西中医药大学第附属医院 | A kind of Chinese medicine package for treating insomnia and preparation method thereof |
| CN111166817A (en) * | 2020-02-14 | 2020-05-19 | 江西中医药大学 | Compound essential oil for improving sleep, tranquilizing mind and relieving depression and composition thereof |
| CN111317753A (en) * | 2020-03-11 | 2020-06-23 | 北京茂思商贸有限公司 | Plant essential oil composition with effects of calming and helping sleep and preparation method thereof |
-
2022
- 2022-03-28 CN CN202210313896.3A patent/CN114652784B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114652784A (en) | 2022-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20120131970A (en) | Perfume composition with antistress and relexing effect, and cosmetic composition comprising the same | |
| CN104271141A (en) | Ellagitannins rich extracts composition | |
| Edwards | The Aromatherapy Companion: Medicinal Uses/Ayurvedic Healing/Body-Care Blends/Perfumes & Scents/Emotional Health & Well-Being | |
| CN104740011A (en) | Essential oil for calming nerves and promoting sleep and preparation method thereof | |
| CN105748953A (en) | Traditional Chinese medicine composition with functions of treating insomnia, improving senile dementia, enhancing learning and memory abilities and resisting to depression and anxiety | |
| CN114652784B (en) | Compound essential oil with sedative hypnotic and memory improving effects and preparation method thereof | |
| CN110655990A (en) | Preparation method and application of traditional Chinese medicine wormwood essential oil | |
| KR20180083719A (en) | A aromatic composition having anti-stress and fatigue relaxing, and a cosmetic composition containing the same | |
| KR102316168B1 (en) | Aroma oil serum composition comprising frankincense oil | |
| Wilson | Aromatherapy: essential oils for vibrant health and beauty | |
| Stiles | The essential oils complete reference guide: Over 250 recipes for natural wholesome aromatherapy | |
| Taber et al. | Endocannabinoids: stress, anxiety, and fear | |
| KR101232349B1 (en) | Fragrance composition for providing sedative effect and leading sound sleep | |
| CN110624029A (en) | Traditional Chinese medicine composition for resolving depression, calming heart and soothing nerves and preparation method of external patch | |
| US20190083564A1 (en) | Neurological Essential Oil Composition and Methods | |
| CN109432318B (en) | Compound essential oil, application thereof and compound essential oil product | |
| Webb | Aromatherapy | |
| JP2010285362A (en) | Therapeutic agent for dementia patient and kit for treating dementia patient | |
| Dimova | Use of Essential Oils in Medicine and Spa | |
| Eric Zielinski et al. | The Essential Oils Apothecary: Advanced Strategies and Protocols for Chronic Disease and Conditions | |
| KR101791217B1 (en) | A composition for enhancing concentration and memory containing Thuja orientalis oil extract as an active ingredient | |
| Sharma | Aroma Therapy | |
| LU503397B1 (en) | Application of volatile oil of traditional chinese medicine in preparation of antidepressant drug and aromatherapy product | |
| CN106727770A (en) | Application of the storax in antidepression, anxiety product is prepared | |
| CN114984121B (en) | A Chinese medicinal composition with effects of refreshing and relieving fatigue, and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240129 Address after: No. 1688, Meiling Avenue, Wanli District, Nanchang City, Jiangxi Province, 330103 Patentee after: JIANGXI University OF TRADITIONAL CHINESE MEDICINE Country or region after: China Patentee after: ACADEMY OF MILITARY MEDICAL SCIENCES Address before: 330000 Xingwan Avenue 818, Wanli District, Nanchang City, Jiangxi Province Patentee before: JIANGXI University OF TRADITIONAL CHINESE MEDICINE Country or region before: China |